CIK 0001991792 · Large accelerated filer
CG Oncology, Inc.
Sign in to watch- Ticker
- CGON
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371611499
- Phone
- (949) 409-3700
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $135,045
- in 2 filings, $135K under 10b5-1 plans
Net −$135,045. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-06 | POST LEONARD E Director | Option exercise · Stock Option 10b5-1 | −1,000 | 134,077 | ||
| 2024-10-04 | Roche Corleen M. CFO | Grant or award · Stock Option (Right to Buy) | +93,600 | 93,600 | ||
| 2024-10-04 | POST LEONARD E Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Graf Susan E Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Liu Brian Guan-Chyun Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Tong Victor Edward Jr Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Kasturi Vijay Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +132,600 | 132,600 | ||
| 2024-10-04 | Song Hong Fang Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Mulay James Director | Grant or award · Stock Option (Right to Buy) | +15,600 | 15,600 | ||
| 2024-10-04 | Bellete Ambaw President and COO | Grant or award · Stock Option (Right to Buy) | +175,500 | 175,500 | ||
| 2024-10-04 | Patterson Joshua F. See Remarks | Grant or award · Stock Option (Right to Buy) | +47,775 | 47,775 | ||
| 2024-10-04 | Kuan Arthur Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +397,800 | 397,800 | ||
| 2024-08-29 | Song Hong Fang Director | Sale | −424,210 | $35.36 | $15.0M | 586,982 |
| 2024-08-29 | Song Hong Fang Director | Sale | −226,245 | $35.36 | $8.0M | 3,703,931 |
| 2024-05-15 | Patterson Joshua F. See Remarks | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Purchase | +400,000 | $19.00 | $7.6M | 4,958,810 |
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion | +3,628,198 | 4,558,812 | ||
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Purchase | +400,000 | $19.00 | $7.6M | 400,000 |
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion · Series C Preferred Stock | −8,644,891 | 0 | ||
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion · Series E Preferred Stock | −21,547,685 | 0 |
Page 8 of 9 · 172 trades